Skip to main content

Table 2 Clinical parameters and biomarker levels of axSpA at baseline and after 6 months of exercise therapy

From: Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis

  All axSpA nr-axSpA AS
(n = 40) (n = 18) (n = 22)
Baseline 6 months P value Baseline 6 months P value Baseline 6 months P value
ASDAS-CRP 2.10 ± 0.12 1.84 ± 0.11 <0.01 2.01 ± 0.19 1.73 ± 0.16 <0.05 2.17 ± 0.16 1.93 ± 0.15 ns
BASDAI 2.78 ± 0.31 2.30 ± 0.25 ns 2.98 ± 0.28 2.27 ± 0.41 ns 2.63 ± 0.35 2.31 ± 0.32 ns
BASFI 1.06 ± 0.16 1.01 ± 0.14 ns 1.23 ± 0.28 1.73 ± 0.16 ns 0.92 ± 0.17 0.93 ± 0.18 ns
BASMI 1.28 ± 0.14 0.66 ± 0.84 <0.0001 1.09 ± 0.12 0.47 ± 0.08 <0.0001 1.43 ± 0.24 0.82 ± 0.23 <0.0001
CRP (mg/l) 4.67 ± 0.89 3.86 ± 0.82 ns 2.10 ± 0.48 2.16 ± 0.56 ns 6.76 ± 1.45 5.24 ± 1.37 ns
IL-6 (pg/ml) 10.31 ± 3.93 10.07 ± 4.60 ns 14.78 ± 8.35 15.40 ± 9.79 ns 6.48 ± 1.46 5.51 ± 1.63 ns
IL-17 (pg/ml) 323.50 ± 57.06 401.50 ± 75.87 ns 349.20 ± 82.55 285.30 ± 72.73 ns 301.80 ± 80.57 499.30 ± 123.10 ns
TNF-α (pg/ml) 65.22 ± 12.30 56.89 ± 10.61 ns 55.87 ± 10.49 45.03 ± 6.76 ns 72.49 ± 20.45 62.12 ± 18.06 ns
Calprotectin (ng/ml) 2408.0 ± 183.30 1800.0 ± 101.90 <0.001 2379.0 ± 243.20 1779.0 ± 138.30 <0.01 2430.0 ± 269.70 1816.0 ± 148.20 <0.01
  1. The statistical significance was determined as a p value < 0.05; the paired non parametric test (Wilcoxon) was used for analysis of baseline versus 6 month data for each group. All data are characterised as mean ± standard deviation. axSpA axial spondyloarthritis, nr-axSpA non-radiographic axial spondyloarthritis, AS ankylosing spondylitis, ASDAS-CRP AS disease activity score, CRP C-reactive protein, BASDAI Bath AS disease activity index, BASFI Bath AS functional index, BASMI Bath AS metrology index, IL interleukin, TNF tumour necrosis factor, ns not significant